Beth Hoffman

Company: Origami Therapeutics, Inc.
Job title: Founder & Chief Executive Officer
Seminars:
4.00 Optimizing Protein Degraders for Neurodegeneration 9:30 am
Considerations for optimizing the best leads Use of patient iPSC-derived neurons as a translational model Demonstration of PK/PD relationships in preclinical rodent modelsRead more
day: Day One Track B PM